Nasdaq ikna.

Ikena Oncology, Inc. (NASDAQ:IKNA) announced its earnings results on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02. The business earned $3.75 million during the quarter, compared to analysts' expectations of $2.92 million.Mar 7, 2023 · Follow. BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ... On September 12, 2023, BVF Inc. IL announced that it had increased its position in Ikena Oncology, Inc. (NASDAQ: IKNA) by 26.6% during the first quarter of this year. According to the company’s recent Form 13F filing with the Securities and Exchange Commission, BVF Inc. IL now owns a total of 3,169,164 shares of Ikena Oncology after acquiring an …Overview News Ikena Oncology Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.62 Market Cap 72.39 M Public Float N/A N/A …The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market ® that are classified as either biotechnology or pharmaceutical according to the Industry ...

30 minutes. No description. Ikena™ is redefining the targeted oncology landscape and envisions a world in which every cancer patient has a cure. We develop therapies that target the underlying mechanisms driving cancer survival and growth.Ikena Oncology (NASDAQ:IKNA) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. Ikena Oncology beat ...

Mar 7, 2022 · BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it ... ... (NASDAQ: NTLA), and Korro Bio. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA) and Scorpion Therapeutics. His prior investments ...

First Quarter 2022 Financial results. Ikena had $212.4 million in cash, cash equivalents, marketable securities as of March 31, 2022, as compared to $232.2 million as of December 31, 2021. Ikena ...15 mai 2023 ... (NASDAQ: IKNA) (“Ikena” or the “Company”) is a targeted oncology company, focused on developing differentiated therapies for patients in ...Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...Ikena Oncology, Inc. Common Stock (IKNA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Nov 28, 2022 · BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, has been nominated as the company’s first development ...BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Find the latest historical data for KludeIn I Acquisition Corp. Class A Common Stock (INKA) at Nasdaq.com.BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...The stock of Ikena Oncology Inc (NASDAQ: IKNA) has increased by 20.81 when compared to last closing price of 1.49.Despite this, the company has seen a gain of 23.29% in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to ...

Ikena Oncology, Inc. ( NASDAQ:IKNA ) shareholders will doubtless be very grateful to see the share price up 60% in the...Jun 22, 2022 · BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...Aug 7, 2023 · Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ... Nov 24, 2023 · Why Ikena Oncology (IKNA) Might Surprise This Earnings Season finance.yahoo.com - May 10 at 11:04 AM: Equities Analysts Offer Predictions for Ikena Oncology, Inc.'s Q1 2023 Earnings (NASDAQ:IKNA) marketbeat.com - May 8 at 1:22 AM: Ikena Oncology (NASDAQ:IKNA) Receives New Coverage from Analysts at HC Wainwright marketbeat.com - May 5 at 11:17 AM A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In March 2022, Ikena Oncology had US$212m in cash, and was debt-free ...BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today ...

To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. Media Contact Emily Pan [email protected] +1 (646 ...

The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts.IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ...Home IKNA • NASDAQ. Ikena Oncology Inc. Follow. Share. $3.61. Oct 19, 12:03:05 PM GMT-4 · USD · NASDAQ · Disclaimer. search Compare to. Lexicon Pharmaceuticals Inc. Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...Financial Results for the Year Ended December 31, 2022. As of December 31, 2022, Ikena had $156.9 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient ...Nov 24, 2023 · Ikena Oncology (NASDAQ:IKNA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment?We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk. Ikena Oncology, Inc. is traded on the NASDAQ under the ticker symbol "IKNA". What is Ikena Oncology's primary industry? Company operates in the Healthcare ...BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Dec 1, 2023 · In the previous quarter, Ikena Oncology (NASDAQ:IKNA) reported ($0.40) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.44) by $0.04. Learn more on analysts' earnings estimate vs. IKNA's actual earnings.

10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: IKNA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week. Volatility Over Time: IKNA's weekly volatility has increased from 16% to 23% over the past year.

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Nov 9, 2023 · Selected Balance Sheet Items: September 30, 2023 December 31, 2022: Cash and cash equivalents $ 121,277 $ 59,919 Marketable securities $ 75,656 30 minutes. No description. Ikena™ is redefining the targeted oncology landscape and envisions a world in which every cancer patient has a cure. We develop therapies that target the underlying mechanisms driving cancer survival and growth.17 déc. 2021 ... ... (NASDAQ: ADGI), Icosavax (NASDAQ: ICVX), Imago BioSciences (NASDAQ: IMGO), Ikena Oncology (NASDAQ: IKNA), Nuvation Bio (NYSE: NUVB), Sana ...17 déc. 2021 ... ... (NASDAQ: ADGI), Icosavax (NASDAQ: ICVX), Imago BioSciences (NASDAQ: IMGO), Ikena Oncology (NASDAQ: IKNA), Nuvation Bio (NYSE: NUVB), Sana ...In September 2022, Ikena Oncology had US$174m in cash, and was debt-free. Importantly, its cash burn was US$72m over the trailing twelve months. Therefore, from September 2022 it had 2.4 years of ...Mar 17, 2022 · BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ... Biogen Inc. (NASDAQ:BIIB) announced negative topline results from the Phase 3 STAR study of timrepigene emparvovec, an investigational gene therapy for the potential treatment of choroideremia.May-16-23 08:29AM · Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts. (Simply Wall St.) -12.00% ; 09: ...

BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Ikena Oncology (NASDAQ:IKNA) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. Ikena Oncology beat ... Find the latest Institutional Holdings data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.Instagram:https://instagram. free day trading appforex or optionssmall cap growth stocksreality income stock price Oct 7, 2021 · BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ... pennie vision insurancelidar stock price Analyst Forecast According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $14.25, which is an increase of …Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ... guadalajara open tennis Financial Results for the Quarter Ended June 30, 2023. As of June 30, 2023, Ikena had $157.3 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ...Home IKNA • NASDAQ. Ikena Oncology Inc. Follow. Share. $3.61. Oct 19, 12:03:05 PM GMT-4 · USD · NASDAQ · Disclaimer. search Compare to. Lexicon Pharmaceuticals Inc.